281 related articles for article (PubMed ID: 31713958)
1. Variability of Pneumocystis jirovecii prophylaxis use among pediatric solid organ transplant providers.
Paulsen G; Michaels MG; Danziger-Isakov L; Dipchand AI; Green M; McCulloch M
Pediatr Transplant; 2020 Feb; 24(1):e13609. PubMed ID: 31713958
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
[TBL] [Abstract][Full Text] [Related]
3. Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation.
Werbel WA; Ison MG; Angarone MP; Yang A; Stosor V
Transpl Infect Dis; 2018 Jun; 20(3):e12876. PubMed ID: 29512868
[TBL] [Abstract][Full Text] [Related]
4. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past.
Wang EH; Partovi N; Levy RD; Shapiro RJ; Yoshida EM; Greanya ED
Transpl Infect Dis; 2012 Oct; 14(5):519-25. PubMed ID: 22571389
[TBL] [Abstract][Full Text] [Related]
5. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
[TBL] [Abstract][Full Text] [Related]
6. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
[TBL] [Abstract][Full Text] [Related]
7. Pneumocystis jiroveci pneumonia in patients with inflammatory bowel disease: a survey of prophylaxis patterns among gastroenterology providers.
Okafor PN; Wasan SK; Farraye FA
Inflamm Bowel Dis; 2013; 19(4):812-7. PubMed ID: 23435401
[TBL] [Abstract][Full Text] [Related]
8. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
[TBL] [Abstract][Full Text] [Related]
9. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
Awad M; Sierra CM; Mesghali E; Bahjri K
J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
[TBL] [Abstract][Full Text] [Related]
10. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.
Tu GW; Ju MJ; Xu M; Rong RM; He YZ; Xue ZG; Zhu TY; Luo Z
Nephrology (Carlton); 2013 Nov; 18(11):736-42. PubMed ID: 24571744
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis jiroveci pneumonia in kidney and simultaneous pancreas kidney transplant recipients in the present era of routine post-transplant prophylaxis: risk factors and outcomes.
Garg N; Jorgenson M; Descourouez J; Saddler CM; Parajuli S; Astor BC; Djamali A; Mandelbrot D
BMC Nephrol; 2018 Nov; 19(1):332. PubMed ID: 30463516
[TBL] [Abstract][Full Text] [Related]
12. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
13. [Prophylaxis against Pneumocystis pneumonia in pediatric and adult patients undergoing solid organ or hematopoietic stem cells transplantation].
Gambra MP; Bidart T
Rev Chilena Infectol; 2012 Sep; 29 Suppl 1():S19-22. PubMed ID: 23282551
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.
Gupta D; Zachariah A; Roppelt H; Patel AM; Gruber BL
J Clin Rheumatol; 2008 Oct; 14(5):267-72. PubMed ID: 18679133
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and outcomes of Pneumocystis pneumonia in solid organ transplant recipients: Impact of posttransplant lymphoproliferative disorder.
Yetmar ZA; Duffy D; Smith BH; Vikram HR; Brumble L; Limper AH; Beam E
Clin Transplant; 2023 Sep; 37(9):e15021. PubMed ID: 37195184
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
17. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
[TBL] [Abstract][Full Text] [Related]
18. UK survey of Pneumocystis jirovecii pneumonia (PJP) prophylaxis use in paediatric oncology patients.
Proudfoot R; Cox R; Phillips B; Wilne S
Arch Dis Child; 2015 Jan; 100(1):115. PubMed ID: 25324566
[No Abstract] [Full Text] [Related]
19. Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors.
Proudfoot R; Phillips B; Wilne S
J Pediatr Hematol Oncol; 2017 Apr; 39(3):194-202. PubMed ID: 28267082
[TBL] [Abstract][Full Text] [Related]
20. The risk factor analysis and treatment experience in pneumocystis jirovecii pneumonia after kidney transplantation.
Yang P; Zhu X; Liang W; Cai R
Mycoses; 2021 May; 64(5):495-502. PubMed ID: 33368732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
